IBSA Institut Biochimique SA
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 1945-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ibsagroup.com
Clinical Trials
51
Active:13
Completed:31
Trial Phases
5 Phases
Phase 1:13
Phase 2:3
Phase 3:20
+2 more phases
Drug Approvals
32
CANADA:14
SFDA:3
NMPA:1
Drug Approvals
Urofollitropin for Injection
- Product Name
- 注射用尿促卵泡素
- Approval Number
- 国药准字HJ20080050
- Approval Date
- Jan 26, 2025
NMPA
Clinical Trials
Distribution across different clinical trial phases (44 trials with phase data)• Click on a phase to view related trials
Phase 3
20 (45.5%)Phase 1
13 (29.5%)Phase 4
5 (11.4%)Not Applicable
3 (6.8%)Phase 2
3 (6.8%)Pharmacokinetics of FSH and hCG After a Single Subcutaneous Injection of Gonadotropins-IBSA
Phase 1
Recruiting
- Conditions
- OVARIAN STIMULATIONInfertility
- Interventions
- Drug: Gonadotropins Subcutaneos
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- IBSA Institut Biochimique SA
- Target Recruit Count
- 28
- Registration Number
- NCT06781957
- Locations
- 🇨🇦
Syneos Health, Québec, Canada
Pharmacokinetics of FSH and hCG Following Multiple Dose of Gonadotropins-IBSA.
Phase 1
Recruiting
- Conditions
- Ovarian StimulationInfertility
- Interventions
- Drug: Gonadotropins Subcutaneous
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- IBSA Institut Biochimique SA
- Target Recruit Count
- 28
- Registration Number
- NCT06659692
- Locations
- 🇨🇦
Syneos Health, Québec, Canada
TreatMent Of Knee osTeoarthritis wIth chONdroitin Sulfate - the OA MOTION Study
Phase 3
Withdrawn
- Conditions
- Knee Osteoarthritis
- Interventions
- Other: Placebo
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- IBSA Institut Biochimique SA
- Registration Number
- NCT05632783
A New Sildenafil Oral Film in Patients with Erectile Dysfunction
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- IBSA Institut Biochimique SA
- Target Recruit Count
- 488
- Registration Number
- NCT05490680
- Locations
- 🇺🇸
G & L Research LLC., Foley, Alabama, United States
🇺🇸Medical Affiliated Research Center, Huntsville, Alabama, United States
🇺🇸Arkansas Urology Research Center, Little Rock, Arkansas, United States
Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)
Phase 4
Terminated
- Conditions
- Congenital Hypothyroidism
- Interventions
- Drug: Tirosint®-SOL
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- IBSA Institut Biochimique SA
- Target Recruit Count
- 34
- Registration Number
- NCT05228184
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸CHOC Children's Hospital, Orange, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found